Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
The initial dose of this medicine should be determined according to the patient’s current treatment regimen.
1. Patients not currently receiving metformin:
For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients).
2. Patients receiving metformin:
- The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose.
- Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin.
3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Patients with hepatic impairment
This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
Improvement of glycemic control in type 2 diabetes mellitus
Type 2 diabetes
difficulties in blood sugar control
View approved original textHide original text
This medication is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. It is effective for patients who have not previously taken diabetes medications or who find it difficult to control blood sugar through monotherapy. Additionally, it can be used when blood sugar control is inadequate with either metformin or sitagliptin monotherapy or when transitioning therapy that combines both medications. Furthermore, it is used alongside metformin when patients already taking it along with sulfonylureas or thiazolidinediones are not achieving sufficient blood sugar control. Lastly, when control is difficult with insulin and metformin combination therapy, this medication may be added to improve blood sugar control. Thus, it is used effectively in various treatment situations to improve blood sugar control.
How to take
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
The initial dose of this medicine should be determined according to the patient’s current treatment regimen.
1. Patients not currently receiving metformin:
For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients).
2. Patients receiving metformin:
- The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose.
- Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin.
3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Patients with hepatic impairment
This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
Precautions
This medication can cause severe allergic reactions; therefore, if symptoms such as skin rashes or shortness of breath occur within 3 months of administration, immediately stop use and consult a physician.
This medication may induce pancreatitis, so notify healthcare providers if symptoms such as abdominal pain, vomiting, or fever occur.
This medication should not be used in patients with severely impaired kidney function or acute illness.
Before undergoing surgery or tests involving iodine contrast, temporary cessation of this medication is necessary, and it should be resumed only after confirming normal kidney function.
Women who are pregnant or may become pregnant, as well as nursing mothers, are advised not to take this medication.
Maintain regular meals and exercise while taking this medication, and have regular checks of blood sugar and kidney function.
Hypoglycemia may occur, particularly when used with insulin or other antidiabetic agents, so extra caution is advised.
This medication is not recommended for patients with liver dysfunction, and alcohol consumption should be avoided due to the increased risk of lactic acidosis.
If severe joint pain or blisters on the skin develop during treatment, promptly consult a healthcare provider.
Consult healthcare providers immediately if sudden muscle pain, fatigue, or shortness of breath occurs during treatment.
In case of overdose, immediate treatment is necessary, as some components may be removed through hemodialysis.
Elderly patients may have decreased kidney function; thus, dose adjustments and regular kidney function monitoring are necessary.
This medication may interact with other drugs, so inform your doctor or pharmacist about any other medications being taken.
Side effects
anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
diarrhea
upper respiratory tract infection
headache
nausea
Show 22 moreCollapse
vomiting
abdominal pain
nasopharyngitis
peripheral edema
severe joint pain with disability
bullous pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
dermatitis
loss of appetite
weight loss
dyspnea
unstable angina
dizziness
acute renal failure
decreased appetite
gastrointestinal disturbances
itching
Not everyone experiences these, and they can vary from person to person.
Storage
Store this medication in a tightly sealed container to prevent air or moisture exposure, preferably at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer period.
Appearance and packaging
Appearance
Pink oval film-coated tablet
Package unit
30 tablets/box [(10 tablets/PTP x 3)]
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.